(+)-Ochromycinone is a natural antibiotic that effectively inhibits STAT3 and may be used in cancer and psoriasis research.
(+)-Ochromycinone (also known as STA-21) is a natural benz[a]anthraquinone antibiotic originally isolated from Streptomyces species. It is a potent STAT3 inhibitor with an IC50 of approximately 4.8 microM and is being investigated for treating psoriasis and cancers. It is currently in clinical trials (NCT01047943). Target: STAT3 (signal transducer and activator of transcription 3). (+)-Ochromycinone inhibits STAT3 by binding to its SH2 domain, blocking phosphorylation, dimerization, and nuclear translocation. This suppresses transcription of STAT3-dependent genes involved in cell proliferation, survival, and angiogenesis. In vitro, (+)-Ochromycinone potently inhibits STAT3 activity at 4.8 microM. It reduces viability and induces apoptosis in STAT3-dependent cancer cell lines such as breast, prostate, and pancreatic cancer cells. It also suppresses keratinocyte proliferation and inflammatory cytokine production. In vivo, (+)-Ochromycinone is orally bioavailable and has demonstrated efficacy in mouse xenograft models of breast and prostate cancer, reducing tumor growth. In psoriasis models, topical application of an ointment formulation (STA-21 Ointment) reduced skin inflammation and lesion formation. For cell-free assays: recombinant STAT3 protein is incubated with various concentrations of (+)-Ochromycinone in binding buffer, then biotinylated phosphotyrosyl peptide is added. After incubation, samples are transferred to streptavidin-coated plates, washed, and bound STAT3 is detected with anti-STAT3 antibody followed by absorbance measurement. For cell assays: STAT3-dependent cancer cell lines are treated with (+)-Ochromycinone (0-20 microM, 24-72 h). Cell viability is assessed by MTT or CCK-8 assay. Apoptosis is measured by flow cytometry using Annexin V/PI staining. STAT3 phosphorylation is detected by Western blot. For animal studies: in cancer xenograft models, mice with established subcutaneous tumors are treated daily with oral (+)-Ochromycinone (25-100 mg/kg) for 2-4 weeks. Tumor volume and body weight are monitored. For psoriasis models, topical formulation is applied to imiquimod-induced psoriasiform skin lesions in mice. PK properties in mice after oral administration: Tmax approximately 2-4 h, elimination half-life 6-8 h, moderate oral bioavailability (~30-40%), and high plasma protein binding. Longer half-life formulations are being explored for clinical application. No major toxicity concerns have been reported in preclinical studies at efficacious doses. Minor gastrointestinal disturbances were noted at very high doses. In clinical trials, no severe adverse events have been reported to date. (+)-Ochromycinone is a natural antibiotic and STAT3 inhibitor in clinical development for psoriasis (NCT01047943). It is also extensively used in cancer research as a chemical probe for STAT3 validation. It is not yet FDA-approved but shows promise as a targeted therapy for STAT3-driven malignancies.

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.